Reneo Pharmaceuticals Achieves Target Enrollment in the Pivotal STRIDE Study of Mavodelpar (REN001) in Primary Mitochondrial Myopathies
14 mars 2023 07h30 HE
|
Reneo Pharmaceuticals, Inc.
IRVINE, Calif., March 14, 2023 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical-stage pharmaceutical company focused on the development and commercialization of therapies...
Reneo Pharmaceuticals to Present Preclinical Mavodelpar (REN001) Data at the Society for Inherited Metabolic Disorders Annual Meeting 2023
09 mars 2023 08h00 HE
|
Reneo Pharmaceuticals, Inc.
IRVINE, Calif., March 09, 2023 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical-stage pharmaceutical company focused on the development and commercialization of therapies...
Reneo Pharmaceuticals to Participate in SVB Securities Global Biopharma Conference
02 févr. 2023 07h35 HE
|
Reneo Pharmaceuticals, Inc.
IRVINE, Calif., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies...
Reneo Pharmaceuticals Receives Fast Track Designation from the FDA for Mavodelpar (REN001) in a Genotype of Long-Chain Fatty Acid Oxidation Disorder (LC-FAOD)
31 janv. 2023 07h35 HE
|
Reneo Pharmaceuticals, Inc.
IRVINE, Calif., Jan. 31, 2023 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical-stage pharmaceutical company focused on the development and commercialization of therapies...
Reneo Pharmaceuticals Reports Third Quarter 2022 Financial Results
08 nov. 2022 07h35 HE
|
Reneo Pharmaceuticals, Inc.
IRVINE, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical-stage pharmaceutical company focused on the development and commercialization of therapies...
Reneo Pharmaceuticals to Participate at Upcoming Investor Conferences
03 nov. 2022 08h00 HE
|
Reneo Pharmaceuticals, Inc.
IRVINE, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies...
Reneo Pharmaceuticals to Participate at Upcoming Investor Conferences
06 sept. 2022 08h35 HE
|
Reneo Pharmaceuticals, Inc.
IRVINE, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies...
Reneo Pharmaceuticals Announces Poster Presentations at the International Network for Fatty Acid Oxidation Research and Management Annual Meeting
29 août 2022 07h35 HE
|
Reneo Pharmaceuticals, Inc.
IRVINE, Calif., Aug. 29, 2022 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies...
Reneo Pharmaceuticals Reports Second Quarter 2022 Financial Results
09 août 2022 08h00 HE
|
Reneo Pharmaceuticals, Inc.
IRVINE, Calif., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical-stage pharmaceutical company focused on the development and commercialization of therapies...
Reneo Pharmaceuticals Appoints Roshawn Blunt to its Board of Directors
02 août 2022 07h30 HE
|
Reneo Pharmaceuticals, Inc.
IRVINE, Calif., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies...